Several other research firms also recently commented on MDXG. BidaskClub raised shares of MiMedx Group from a hold rating to a buy rating in a report on Wednesday, January 31st. Needham & Company LLC downgraded shares of MiMedx Group from a strong-buy rating to a hold rating in a report on Tuesday, February 20th. Lake Street Capital set a $18.00 price target on shares of MiMedx Group and gave the company a buy rating in a report on Thursday, December 14th. Zacks Investment Research downgraded shares of MiMedx Group from a hold rating to a sell rating in a report on Friday, December 8th. Finally, Piper Jaffray Companies reissued a buy rating and issued a $18.00 price target on shares of MiMedx Group in a report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $14.75.
MiMedx Group (MDXG) opened at $7.27 on Tuesday. The company has a market cap of $816.11, a P/E ratio of 23.45, a P/E/G ratio of 0.95 and a beta of 1.08. MiMedx Group has a fifty-two week low of $6.05 and a fifty-two week high of $18.25.
Large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. boosted its holdings in MiMedx Group by 7.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 8,619 shares of the medical equipment provider’s stock valued at $129,000 after purchasing an additional 600 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in MiMedx Group in the 3rd quarter valued at $119,000. BlueCrest Capital Management Ltd bought a new position in MiMedx Group in the 4th quarter valued at $126,000. PVG Asset Management Corp bought a new position in MiMedx Group in the 3rd quarter valued at $127,000. Finally, First Republic Investment Management Inc. bought a new position in MiMedx Group in the 4th quarter valued at $153,000. 71.15% of the stock is owned by hedge funds and other institutional investors.
WARNING: “MiMedx Group’s (MDXG) Buy Rating Reiterated at Craig Hallum” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3228414/mimedx-groups-mdxg-buy-rating-reiterated-at-craig-hallum.html.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.